Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.
{{Drugbox | image = Regorafenib.svg | image_class = skin-invert-image | alt = | caption =
| tradename = Stivarga, Regonix | Drugs.com = | MedlinePlus = a613004 | DailyMedID = Regorafenib | pregnancy_AU = D | pregnancy_category= | routes_of_administration = By mouth | ATC_prefix = L01 | ATC_suffix = EX05
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).